LDS/Medical Tests/CPOX Gene Mutation Analysis

CPOX Gene Mutation Analysis

CPOX gene is located on long arm of chromosome (3q12). CPOX gene encodes for coproporphyrinogen oxidase, the sixth enzyme of the heme biosynthetic pathway. Coproporphyrinogen oxidase is found in the intermembranic mitochondial space and catalyzes oxidative decarboxylation of coproporphyrinogen III to protoporphyrinogen IX. More than 45 gene mutations have been implicated in Hereditary coporphyria which include but are not limited to missense and nonsense variants, micro and macro deletions, insertions, and splice variants.

Hereditary coproporphyria is a hepatic porphyria and is inherited in an autosomal dominant pattern with variable penetrance. The symptoms of Hereditary coproporphyria usually manifest after puberty and can be both acute and chronic. Manifestations include anxiety, restlessness, abdominal pain, nausea, diarrhea, urinary retention, vomiting, constipation, tachycardia, excess sweating, and hypertension. Neurologic manifestations may result in seizures, and proximal-to- diffuse muscle weakness which may compromise respiration. Cutaneous manifestations are rare and may manifest as photosensitivity.

Harderoporphyria is a very rare hepatic porphyria with hematologic manifestations that may resemble erythropoietic porphyria. It is due to biallelic pathogenic CPOX mutations typically involving D400-K404 region of the CPOX gene. This rare condition manifests as neonatal hemolytic anemia that regresses over a period of time into a milder form. In contrast to Hereditary coproporphyria, these patients may present with skin lesions and show fecal accumulation of harderoporphyin.

  • Confirmation of clinical and laboratory diagnosis of hereditary coproporphyria and harderoporphyria
  • Prenatal assessment of hereditary coproporphyria and harderoporphyria in carrier/ affected parents
  • Preimplantation genetic diagnosis of hereditary coproporphyria and harderoporphyria
  • Hereditary coproporphyria: heterozygous or homozygous mutation(s) in an individual confirms clinical and laboratory diagnosis
  • Harderoporphyria: Mutations involving CPOX gene region D400-K404 together with elevated levels of harderoporpohyrin confirms the diagnosis

Negative for mutation analyze (No reportable variants were identified)

Polymerase chain reaction, Conventional Sequencing, Next Generation Sequencing, Gene targeted deletion/duplication analysis, gel electrophoresis.

Whole blood (EDTA). 

Stability

  • Room: 3-5 days
  • Refrigerated: 7-14 days

Other specimens: saliva, buccal swab, skin biopsy.

Urinary aminolevulinic acid (ALA) and/or porphobilinogen (PBG) levels in individuals with clinical suspicion of hereditary coproporphyria, Quantitative fecal porphyrin and urinary porphyrin analysis for differentiation of hereditary coproporphyria from other forms porphyria.
7-14 Days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • JIMD Rep. 2017 march 28; 37:99-106. [PMID: 28349448]
  • Hum Mol Genet. 2005 Oct 15;14(20):3089-98. [PMID: 16159891]
  • J Bioenerg Biomembr. 1995 Apr;27(2):215-9. [PMID: 7592568]
  • J Pediatr Gastroenterol Nutr. 2015 Mar;60(3):e19-22. [PMID: 23969540]
  • Mol Genet Metab. 2019 Mar 6. pii: S1096-7192(19)30084-8. [PMID: 30987916]
  • J Clin Invest. 1983 Sep; 72(3): 1139–1149. [PMID: 6886003]
  • Mol Genet Metab Rep. 2019 Jun; 19: 100457. [PMID: 30828546]
  • J. Inherit. Metab. Dis. 34: 225-231, 2011. [PMID: 21103937]
  • GeneReviews [Internet].Adam MP, Ardinger HH, Pagon RA, et al., editors. Seattle (WA): University of Washington, Seattle; 1993-2019. [PMID: 20301700]
  • Hum Mol Genet. 2005 Oct 15;14(20):3089-98. Epub 2005 Sep 13. [PMID: 16159891